Key Points
Nov 27 (Reuters) - Canada's Xenon Pharmaceuticals (XENE.O) said on Monday its experimental drug to treat major depressive disorder (MDD) had failed to significantly reduce the severity of the condition in a mid-stage study...
Xenon said the study tested two doses of XEN1101 in 168 patients with moderate to severe MDD, with the drug candidate showing a clinically meaningful, but not statistically significant, reduction in depressive symptoms compared with a placebo...
Stifel analyst Paul Matteis, however, said in a note that he believed the data showed the drug held some promise as a treatment for MDD despite not showing statistical significance...
The U.S. health regulator last month rejected Sage Therapeutics (SAGE.O) and partner Biogen's (BIIB.O) pill, Zurzuvae, as a treatment for major depressive disorder, which according to the National Institutes of Health, is one of the most common chronic mental disorders in the United States...
